Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Recent development of molecular-targeted drugs in lung cancer Saijo N; Kenmotsu HIntern Med 2010[]; 49 (18): 1923-34Numerous molecular target drugs have been introduced for the treatment of advanced malignancies. In the treatment of lung cancer, epidermoid growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) demonstrate striking antitumor activity in selected EGFR mutation positive patients. Patient selection by biomarker is extremely important to obtain successful results. The anti-vascular endothelial growth factor (VEGF) antibody, bevacizumab, shows a markedly increased response rate, progression free survival of advanced non-squamous cell lung cancer when combined with cytotoxic drugs. The classification of lung cancer is rapidly changing based on the advances in molecular biology. Here, the recent development of new molecular target drugs against lung cancer is thoroughly reviewed in addition to EGFR-TKIs and bevacizumab with special emphasis on the clinical application.|Angiogenesis Inhibitors/administration & dosage[MESH]|Animals[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/administration & dosage[MESH]|Antineoplastic Agents/*administration & dosage[MESH]|Bevacizumab[MESH]|Clinical Trials as Topic/trends[MESH]|Drug Delivery Systems/*trends[MESH]|ErbB Receptors/antagonists & inhibitors/metabolism[MESH]|Humans[MESH]|Lung Neoplasms/*drug therapy/enzymology/*metabolism[MESH]|Protein Kinase Inhibitors/administration & dosage[MESH]|Vascular Endothelial Growth Factor A/antagonists & inhibitors/metabolism[MESH] |